# NextCure, Inc. Common Stock (NXTC)

> NextCure, Inc. Common Stock (NXTC) trades at $5.98 (+0.00%) as of 4:10:08 PM EST on Nov 11, 2026, -4.78% over the past month. Market cap is $27.38M, with 3.0 days to cover in short interest.

Canonical: https://massive.com/quote/nxtc
Data as of: 2026-11-11T21:10:08.625Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$5.98** +0.00 (+0.00%)
As of 4:10:08 PM EST on Nov 11, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How NextCure, Inc. Common Stock (NXTC) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.00% |
| 1W | +2.22% |
| 1M | -4.78% |
| YTD | -57.86% |
| 1Y | -35.63% |
| 52-wk range | $1.55 – $15.74 |

From daily closes through Nov 11, 2026.

## Key statistics

Today's trading snapshot for NXTC: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $5.00 – $6.30 |
| Open | $5.73 |
| Prev close | $5.98 |
| Volume | 93.17K |
| Market cap | $27.38M |
| Shares out | 3.61M |

## Valuation and profitability ratios

Valuation and profitability ratios for NextCure, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 2.25 |
| P/FCF | — |
| ROE | -351.9% |
| ROA | -189.0% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 10, 2026

## Insider trading

[NextCure, Inc. Common Stock (NXTC) insider trading](https://massive.com/quote/nxtc/insider-trading.md): open-market Form 4 buys and sells by NextCure, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events NextCure, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 10, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 10, 2026, NextCure, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Oct 30, 2026 · Executive compensation change
  “In connection with his departure, Dr. Guha entered into a severance agreement and release with the Company (the "Severance Agreement"). In exchange for a release of claims in favor of the Company, the Severance Agreement provides for severance benefits consistent with those provided for a termination without cause under Dr. Guha's existing employment agreement... Subject to and conditioned upon the occurrence of the closing of the Merger, the Severance Agreement provides for additional severance equal to the enhanced severance benefits for a termination without cause in relation to a change in control, as set forth in Dr. Guha's Employment Agreement.”
- Sep 25, 2026 · [Stock split](https://massive.com/quote/sec-filings/8-k/stock-splits.md)
  “The Company's board of directors approved a 1:12 split, and the Company filed the 2025 Reverse Split Amendment with the Delaware Secretary of State on July 10, 2025. Upon the effectiveness of the 2025 Reverse Split Amendment, every twelve shares of Common Stock then outstanding were combined and converted into one share of Common Stock.”
- Sep 3, 2026 · Material charge or gain
  “In connection with the Amendment, the Company paid a one-time termination fee of approximately $0.8 million and forfeited its security deposit of approximately $39,000.”
- Jul 14, 2026 · Private placement
  “Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement (the 'Purchase Agreement') with Avere, pursuant to which they have agreed, subject to the terms and conditions of the Purchase Agreement, to purchase (including by contribution of Company Notes (as defined in the Merger Agreement)) immediately prior to the First Effective Time, shares of Avere capital stock and pre-funded warrants to purchase shares of Avere capital stock (together, the 'PIPE Securities') for an aggregate purchase price of approximately $320 million in a private placement (the 'Private Placement').”

## Dividend history and stock splits

NextCure, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-12 · Jul 14, 2025

## NXTC short interest

How heavily NXTC is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 3.0 |
| Short interest | 184.03K |
| Avg volume | 61.91K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## NXTC news

The latest news and headlines about NextCure, Inc. Common Stock (NXTC).

- [NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders](https://www.globenewswire.com/news-release/2026/07/14/3327408/0/en/NXTC-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-NextCure-Inc-is-Obtaining-a-Fair-Price-for-its-Shareholders.html) · GlobeNewswire Inc. · Jul 14, 2026 · negative sentiment
- [NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy](https://www.globenewswire.com/news-release/2026/07/14/3326655/0/en/NextCure-and-Avere-Therapeutics-Announce-Merger-to-Advance-Once-Weekly-Oral-IL-23-Therapy.html) · GlobeNewswire Inc. · Jul 14, 2026 · neutral sentiment
- [What's Going On With NextCure Stock Wednesday?](https://www.benzinga.com/trading-ideas/movers/26/06/52968769/whats-going-on-with-nextcure-stock-wednesday?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Jun 3, 2026 · neutral sentiment
- [NextCure Provides Business Update](https://www.globenewswire.com/news-release/2026/01/23/3224596/0/en/NextCure-Provides-Business-Update.html) · GlobeNewswire Inc. · Jan 23, 2026 · neutral sentiment
- [NextCure (NXTC) Q2 Loss Widens 71%](https://www.fool.com/data-news/2025/08/08/nextcure-nxtc-q2-loss-widens-71/?source=iedfolrf0000001) · The Motley Fool · Aug 7, 2025 · negative sentiment

## About NextCure, Inc. Common Stock

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 40 |
| Listed | May 9, 2019 |

[Company website](https://www.nextcure.com)

## FAQ

### What is the NextCure, Inc. Common Stock (NXTC) stock price today?

NextCure, Inc. Common Stock (NXTC) is trading at $5.98 (+0.00% on the day) as of 4:10:08 PM EST on Nov 11, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is NextCure, Inc. Common Stock?

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug…

### What is the short interest in NXTC?

As of Oct 30, 2026, NXTC has 184.03K shares short and 3.0 days to cover.

### What exchange is NXTC listed on?

NextCure, Inc. Common Stock (NXTC) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time NXTC quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=NXTC`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [NextCure, Inc. Common Stock (NXTC) insider trading](https://massive.com/quote/nxtc/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms